Executive group
Dr. Erik Stomrud has no competing interests.
Assoc. prof. Niklas Mattsson-Carlgren has received consultancy/speaker fees from Biogen, Owkin, and Merck.n.
Prof. Oskar Hansson is an employee of Lund University and Eli Lilly.
Assoc prof. Rik Ossenkoppele has received research funding/support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer, is an advisory board member for Asceneuron and a steering committee member for Biogen and Bristol Myers Squibb. All the aforementioned has been paid to his institutions..
Assoc. prof. Sebastian Palmqvist has acquired research support (for the institution) from ki:elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Lilly, Novo Nordisk, and Roche.